Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Current Deferred Revenue (2016 - 2020)

Corbus Pharmaceuticals Holdings has reported Current Deferred Revenue over the past 6 years, most recently at $270530.0 for Q2 2020.

  • For Q2 2020, Current Deferred Revenue fell 89.1% year-over-year to $270530.0; the TTM value through Jun 2020 reached $270530.0, down 89.1%, while the annual FY2018 figure was $35996.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q2 2020 was $270530.0 at Corbus Pharmaceuticals Holdings, down from $2.5 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $27.0 million in Q1 2019 and troughed at $10263.0 in Q4 2016.
  • A 5-year average of $3.5 million and a median of $1.2 million in 2016 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 99.36% in 2016 and later soared 1412.16% in 2018.
  • Year by year, Current Deferred Revenue stood at $10263.0 in 2016, then surged by 2787.18% to $296311.0 in 2017, then tumbled by 87.85% to $35996.0 in 2018, then surged by 6795.87% to $2.5 million in 2019, then plummeted by 89.1% to $270530.0 in 2020.
  • Business Quant data shows Current Deferred Revenue for CRBP at $270530.0 in Q2 2020, $2.5 million in Q2 2019, and $27.0 million in Q1 2019.